Member Info for Adastra

£13.38 should shatter by Friday all being well. Lots of cash sitting on the sidelines awaiting Thurs t/u. The sale of multiple robotic systems into India triggered last Thursdays rise, I expect the trading update and Deepak Naths initial perspective on S&N to precipitate multiple upgrades.

Ironically it took out that peak equivalent in the US last Thursday...... should only be a matter of time as buyers catch up again....

Consolidation over, two days to t/u and end of closed period allowing Deepak to load up.... Got to be time for S&N to attack the £13.38 barrier and take it out before end April.....long overdue.

Quick regroup before t/u and Nath Deepak's initial statement on Thursday. The Indian robotics deals signed this week are only the tip of the iceberg. So much happening below the water, including the re-emergence of t/o gossip with the post-Covid upswing on the immediate horizon. Juicy, and April is indeed proving to be the wake-up call that was long long overdue. Got to hit £18 by end 2022

Now S&N can motor......

YOUR time to shine has just arrived. April, as I predicted is the time when all the pieces coalesce.
Get in there.....happy days. Still plenty of upside to come, today was just the wake up call for this sleeping giant of the 2020's.

As the t/u next week is a quarterly trading update Deepak has been prevented from buying shares effectively from the date of his appointment as CEO. The one month rule applies. I am hopeful that he'll fill his boots on 28th....Great initial purchase price if this low holds for a week...

The biggest boost would be for Deepak to buy a shedload of shares once the t/u is out and he can do so. That would be a whopping vote of confidence and perfect timing at this low point. Great price to stick in this year's ISA....

The end of the $125m share buyback puts S&N in limbo till 28th April t/u. A decent vision forward by new CEO Deepak Nath should give confidence coming out of all Covid restrictions. The more detailed the better and it will be a real indicator of why he took the role and his plans as the business accelerates in 2022 and beyond. Fingers crossed.

Looking at the low volumes over the past 2 weeks I think we've had capitulation by a large number of frustrated PI's who have gone off chasing supposedly better returns. There appears to have been little movement by the Instos. Now that we have hopefully cleared out a lot of stale sellers and the pool has been mopped up we should start to make inroads north. A lot of the bad news regarding waiting lists, covid etc is out there and should now be receding. April 28th is absolutely key now. The trading update and introduction of Deepak Nath as new CEO should have the desired effect in lighting the fuse. I think that the Market has been exceptionally harsh on S&N so any positive comments should be well received. Great time for the company to have understated and over achieved. Just 2 weeks away, we should be pleasantly rewarded for our patience and commitment from here.

Hopefully, this is the last dip below the strategically important £12 level and has allowed stale sellers out allowing 2023 growth funds to take a position. I had expected the new tax year to cause a flurry of buying but everything is subdued at present. This is one of the few shares that can ride a recession.

Sadly S&N just doesn't seem to be on the pension funds radar at present despite multiple analysts quoting it's underlying strengths in a period of general recession. The backlog of work for specialist companies like S&N is enormous and growing daily. The only issue is how quickly the problem can be addressed and when the huge inventory required will be forward ordered. I'd certainly wait till the t/u on April 28th for an indication of traction and Deepak Naths initial assessment and projections as he heads the team now. The share is so beaten down below it's intrinsic fair value I personally, am stunned American players have made a bid. It looks a rock solid investment for a key global major.

Nothing seems to be able to propel this share over the £12.37 and £12.57 hurdles..... horizon scanning shows a clear blue path ahead and yet it stays bogged down feet in the mud. When the wellies finally come off we should see incremental progress and hopefully 28th will be the trigger. I really expected the anticipation to kick in earlier but S&N is proving the exception to the norm. It may well have the capacity to do the same once sentiment switches......unpredictable ....

I do wish S&N had been a little more proactive in engaging with the investment community at a time when so many companies are vying for attention. The departure of Roland Diggelman CEO was RNS'd on 31st but no mention of Deepak Nath starting as new CEO. Yes, the succession had been announced in Feb, but why highlight the minor of the two now. A silly little oversight that would have put S&N in the limelight and given the press opportunity to feature his excellent CV again. Also, last year there was an RNS in March regarding the Q1 t/u in April. This year, despite the t/u being scheduled for April 28th , no RNS. It really is this lack of consistency to detail that really irritates seasoned investors like myself. The share price is bouncing along the bottom, and will rise strongly as sentiment turns, but the company secretary needs to pull up his socks at present. Time to convey strong hands at the tiller and a clear course set. Deepak should certainly shake things up and bring a fresh approach to a fantastic underlying business.

Exactly.......spot on.

Merrill is playing a very decent poker hand at the moment in both tracking and supporting the company as sentiment will undoubtedly turn in the greater investment community. It's purchase of shares on behalf of S&N is carefully loaded in both tracking and supporting the price whilst that sentiment changes. It is counter productive to go heavily on the buy side as you then force yourself to buy at a premium. I have been tracking their daily purchases since February and they have been very cute players. The current average purchase price of all the shares purchased to date is pretty exactly the current price at £12.27 or so.
Merrill is just over half way through it's $125m task and is effectively mopping up all the stale sellers before we get a (hopefully) decent update later this month and news of Deepak's plans moving forward. Neat.

And as Credit Suisse so succinctly puts it....
S&N is “materially undervalued” it has concluded both on a sales and earnings multiple.

I think RBC synopsis is the most pertinent as it is new coverage as opposed to updated. It pretty well sums up the reasons for my own continued investment decision here albeit at a fair premium to the current price but far short of my perceived value.
"The market is not pricing in the potential acceleration in both revenue growth and margins from the company's strong positioning in high-growth Sports Medicine and ASCs, as well as its differentiated CORI surgical robot and new cementless knee portfolio, in our view, as well as its operational improvement programme," RBC said.

"This provides an opportunity to build a position in a major med-tech company at a historically low entry point"

Exactly the same thing happened with Aviva when I invested in September 2020. Unloved, on a progressive low followed by low, but in a positive sector for a rerate. It did, the rest is history. S&N has positioned itself in good growth areas and I see the ability, like Aviva, to repeatedly surprise on the upside this year.

Check my previous posts (particularly 14.26 yesterday). Recent analyst coverage also suggests at out performance. It's a good hedge sector in current climate. Few players, very high barrier to entry and 'must have' life changing products. Supply issues are being addressed and the huge new Malaysian centre/warehouse opens in H2 this year.